Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tim Kummer"'
Autor:
Tim Kummer, Alexandra M. Medley, Alexander Klosovsky, Erin Mann, Patricia Mburu, Karen Ekernas, Betty Bonass, Jacob C. Stauffer, Stewart Walukaga, Michelle Weinberg, Stephen J. Dunlop, William M. Stauffer
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 108:12-14
Ultrasound (US) is an invaluable clinical tool. New point-of-care US technology holds great promise for hard-to-reach and mobile populations such as refugees. The implementation of US in unique and challenging settings has been hindered by cost, frag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e870d37b07ee779767cc0cbf4a93a6d
https://doi.org/10.4269/ajtmh.22-0423
https://doi.org/10.4269/ajtmh.22-0423
Autor:
Malte Monin, Tim Kümmerle, Jochen Schneider, Christiane Cordes, Hans Heiken, Hans-Jürgen Stellbrink, Ivanka Krznaric, Stefan Scholten, Björn Jensen, Heiko Jessen, Wilfried Obst, Petra Spornraft-Ragaller, Pavel Khaykin, Annamaria Balogh, Eva Wolf, Helen Bidner, Christoph D. Spinner, Christoph Boesecke, on behalf of the DUALIS STUDY GROUP
Publikováno v:
HIV Research & Clinical Practice, Vol 23, Iss 1, Pp 15-21 (2022)
Background/Aims: Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to vira
Externí odkaz:
https://doaj.org/article/a20e550effa442568061017841420a2e
Autor:
Eva Wolf, Christoph Boesecke, Annamaria Balogh, Helen Bidner, Christiane Cordes, Hans Heiken, Ivanka Krznaric, Tim Kümmerle, Hans-Jürgen Stellbrink, Jochen Schneider, Christoph D. Spinner, the DUALIS Study Group
Publikováno v:
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-5 (2021)
Abstract Objective The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced
Externí odkaz:
https://doaj.org/article/13c3c10b06e24c7ca75268ee1f49479c
Autor:
Henning Gruell, MD, Jesper D Gunst, MD, Yehuda Z Cohen, MD, Marie H Pahus, Jakob J Malin, MD, Martin Platten, MD, Katrina G Millard, RN, Martin Tolstrup, PhD, R Brad Jones, PhD, Winnifer D Conce Alberto, Julio C C Lorenzi, PhD, Thiago Y Oliveira, PhD, Tim Kümmerle, MD, Isabelle Suárez, MD, Cecilia Unson-O'Brien, PhD, Lilian Nogueira, PhD, Rikke Olesen, PhD, Lars Østergaard, ProfMD, Henrik Nielsen, ProfMD, Clara Lehmann, MD, Michel C Nussenzweig, ProfMD, Gerd Fätkenheuer, ProfMD, Florian Klein, ProfMD, Marina Caskey, ProfMD, Ole S Søgaard, ProfMD
Publikováno v:
The Lancet Microbe, Vol 3, Iss 3, Pp e203-e214 (2022)
Summary: Background: The administration of broadly neutralising anti-HIV-1 antibodies before latency reversal could facilitate elimination of HIV-1-infected CD4 T cells. We tested this concept by combining the broadly neutralising antibody 3BNC117 in
Externí odkaz:
https://doaj.org/article/b572a4bc81f74c27b4e7e697acac132e